Abstract:A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR < 0.5 defines complete response in guidelines and clinical trials when achieved after 1 or 2 years. Biomarkers of early response are needed to guide early treatment changes. We studied longitudinal urine proteomic profiles in LN to identify early predictors of proteinuric response.Identify early predictors of proteinuric response in LN using longitudinal urine proteomic profiles.We quantified 1200 biomarkers (Kiloplex, RayBiotech) in urine samples collected on the day of (73%) or within 3 weeks (27%) of kidney biopsy and week 12, 24, or 52 in LN patients (ISN class III, IV, V, or mixed) with proteinuria > 1 g/d. Response was defined at one year from renal biopsy: Complete = UPCR < 0.5, serum creatinine (sCr) < 125% of baseline, prednisone ≤ 10mg/d; Partial = UPCR < 50% from baseline but >0.5, sCr < 125% of baseline, but prednisone allowed to 15 mg/d; Non responder = not meeting previous definitions.A total of 127 patients were included: 48 (38%) with pure proliferative LN (class III or IV), 41 (32%) with mixed LN (III or IV +/- V), and 38% (30%) with pure membranous LN. Response was complete in 34 (27%), partial in 29 (23%), and none in 64 (50%). There were no urinary biomarkers at baseline that predicted response. We then analyzed the changes in urinary proteins at 3 months compared to baseline. Patients who responded at 1 year showed an early decline in 51 urinary proteins led by CD163, IL-16, and CD206 (macrophage mannose receptor) (Figure 1A) which matched the proteomic signature associated with histological activity (Figure 1B). No changes were observed in nonresponders. The decline of several urinary biomarkers at 3 months outperformed a decline in UPCR (clinical standard) in predicting the 1 year response. In particular, a decline of CD163 predicted 1 year response in ROC analysis with an area under the curve (AUC) of 83% compared to an AUC of 75% for UPCR decline. In proliferative LN, urinary biomarkers displayed superior performance with an AUC of 91%, 86%, and 78% for the decline of CD206, CD163, and UPCR, respectively (Figure 1C-D). Pathway enrichment analysis identified leukocyte activation, neutrophil degranulation, and matrix degradation as the main pathways reduced at 3 months in responders.Figure 1.An early decline in urinary biomarkers of histological activity is associated with proteinuric response at 1 year. These findings indicate that effective immunosuppression induces by three months an immunological response in the kidney that can be noninvasively monitored in the urine. Biomarkers of immunological response outperformed early decline of UPCR, the standard of care, in predicting 1-year proteinuric response, especially in proliferative LN. Because biomarkers of immunological response parallel intrarenal activity, they could detect early treatment response/failure and allow early treatment changes. They could serve as surrogate endpoints in clinical trials. Longitudinal studies are needed to confirm that this immunological response is a better predictor of long-term kidney function preservation than proteinuric responses.NIL.NIL.None Declared.

276 Baseline renal autophagy-related protein p62 expression level predicts 24-week treatment effectiveness in lupus nephritis

THU0247 LRRN4: A NOVEL PROGNOSTIC BIOMARKER OF RENAL OUTCOME IN LUPUS NEPHRITIS PATIENTS

Early-stage predictors for treatment responses in patients with active lupus nephritis.

The novel involvement of podocyte autophagic activity in the pathogenesis of lupus nephritis.

Podocytes and autophagy: a potential therapeutic target in lupus nephritis

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

Increased Autophagy is Cytoprotective Against Podocyte Injury Induced by Antibody and Interferon-Α in Lupus Nephritis.

Characteristics and Renal Survival of Patients with Lupus Nephritis with Glomerular Immunoglobulin G4 Deposition: a Single-Centre Retrospective Analysis.

[The Expression and Significance of Microtubule-Associated Protein 1 Light Chain 3-Related Protein-1 (LC3) Mrna in Peripheral Blood Mononuclear Cells in Patients with Systemic Lupus Erythematosus].

Increased Urinary Interleukin 22 Binding Protein Levels Correlate with Lupus Nephritis Activity

Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis

CD36 aggravates podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy in lupus nephritis

Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus

OP0211 CHANGE IN URINARY BIOMARKERS AT THREE MONTHS PREDICTS 1-YEAR TREATMENT RESPONSE OF LUPUS NEPHRITIS BETTER THAN PROTEINURIA

Downregulation of autophagy is associated with poor clinical outcome after immunochemotherapy in patients with diffuse large B-cell lymphoma

Long-term Renal Outcomes in a Cohort of 1814 Chinese Patients with Biopsy-Proven Lupus Nephritis.

Remission and remission-related factors in lupus nephritis patients: a cohort study

Impact of baseline proteinuria level on long-term outcomes in lupus nephritis

Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function

Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults

POS0743 GENE EXPRESSION MICROARRAY IN LUPUS NEPHRITIS BY BIOINFORMATIC ANALYSIS